Costco, Coca-Cola and AstraZeneca lead Zacks' top stock reports as strong earnings, growth drivers and pipeline momentum lift ...

AstraZeneca’s Fasenra (benralizumab) has been approved by the US FDA for the treatment of adult and paediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an ...

A drug developed by AstraZeneca and Daiichi Sankyo to treat breast cancer has been approved by the Food and Drug Administration. Enhertu was approved for two new breast cancer indications for use ...

Nvidia’s market capitalisation ($5.7 trillion) has overtaken Germany’s GDP ($5.45 trillion). The combined value of the five ...

In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients ...

Some 63% of all analyst ratings on FTSE shares are currently set to Buy. Here are three stocks the experts believe could lead ...

U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of ...

Approved for use before surgery based on DESTINY-Breast11 phase 3 trial or following surgery based on DESTINY-Breast05 phase 3 trial. Two new indications bring Daiichi Sankyo and ...

Hypereosinophilic syndrome is defined by persistent eosinophilia with eosinophil-mediated organ/tissue damage, driving ...

AstraZeneca AZN and AbbVie ABBV are leading U.S. drugmakers with strong positions in high-growth therapeutic areas like ...

News, features, and commentary about cancer-related issues ...